Serelaxin

DB05794InvestigationalProtein Based Therapies

Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where...

Mechanism: Recombinant human relaxin inhibits contractions of the uterus and may play a role in timing of delivery. Relaxin works by simultaneously cutting collagen production and increasing collagen breakdown.
Curator reviewed
Primary indication: Investigated for use/treatment in cardiovascular disorders, congestive heart failure, infertility, peripheral vascular disease, and scleroderma.Curator reviewed
Formula / weight: C₆H₁₁MgO₇ · 219.4523 Da
Also known as: Human relaxin 2 (relaxin h2) · Human relaxin recombinant · Recombinant human relaxin
Code names: RLX030

Resolves to

Compound

UNIIW0122B976YCAS99489-94-8

Clinical / RWD

ATCC01DX21

Targets

Q8WXD0RXFP2Q9HBX9RXFP1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 2 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Serelaxin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account